Trial Profile
MN-221-CL-007: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2017
Price :
$35
*
At a glance
- Drugs Bedoradrine (Primary) ; Ipratropium bromide; Salbutamol
- Indications Acute asthma; Status asthmaticus
- Focus Therapeutic Use
- Sponsors MediciNova
- 14 Nov 2012 Results will be presented at the Fourth World Congress of Emergency Medicine, according to a MediciNova media release.
- 23 May 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met.
- 23 May 2012 Preliminary results were reported in a MediciNova media release.